PVLA — Palvella Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology
$150.13
-$0.42 (-0.28%)
Palvella Therapeutics, Inc (PVLA) is a biotechnology company listed on NASDAQ. It is led by Wesley H. Kaupinen, based in 353 W. Lancaster Avenue, Wayne, PA, United States, 19087, with about 29 employees. Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Net income was -$29.0M. PVLA currently screens at market cap $1.64B.
Use this PVLA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PVLA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PVLA SEC filings page. Lician reads the product cache first so this HTML stays unique to Palvella Therapeutics, Inc even when a live quote feed is slow.
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
PVLA Key Statistics
Market Cap
$1.64B
Volume
113,775
Previous Close
$154.33
Day Range
$149.04 – $156.03
P/B Ratio
6.95
EPS
-$7.83
Revenue
$0.00
Net Income
-$17.43M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
29
PVLA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $42.81M | $25.90M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.43M | $18.69M | -$33.28M |
| EPS (Diluted) | -$7.83 | $2.17 | $0.00 |
Total Assets
$88.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$83.60M
Operating Cash Flow
-$10.84M
Free Cash Flow
$0.00
Palvella Therapeutics, Inc Company Information
- Founder, President, CEO & Director
- Wesley H. Kaupinen
- Headquarters
- 353 W. Lancaster Avenue, Wayne, PA, United States, 19087
- Website
- palvellatx.com
- Phone
- 484 253 1461
- IPO / Founded
- 2024-12-16
- Sector
- Healthcare
- Industry
- Biotechnology